Article
A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.
The Journal of experimental medicine - 7 Dec 2020
Oda Shannon K, Anderson Kristin G, Ravikumar Pranali, Bonson Patrick, Garcia Nicolas M, Jenkins Cody M, Zhuang Summer, Daman Andrew W, Chiu Edison Y, Bates Breanna M, Greenberg Philip D
Abstract excerpt
Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can be limited by restrictive tumor microenvironments (TMEs). For example, Fas ligand is commonly overexpressed in TMEs and induces apoptosis in tumor-infiltrating, Fas receptor-positive lymphocytes. We engineered immunomodulatory fusion proteins (IFPs) to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.